NCT04655222View on ClinicalTrials.gov

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

CompletedOBSERVATIONAL
Enrollment

470

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

October 15, 2021

Study Completion Date

October 15, 2021

Conditions
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Interferon Beta Therapy

Administered as specified in the treatment arm.

Trial Locations (1)

Unknown

Research Site, Göttingen

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT04655222 - Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program | Biotech Hunter | Biotech Hunter